Innovative TLC-densitometric method with fluorescent detection for simultaneous determination of ternary anti-diabetic mixture in pharmaceutical formulations and human plasma
Abstract
Abstract Co-administration of Glimepiride (GLIM), Empagliflozin (EMPA) and Linagliptin (LING) promote a preferred glycemic control, besides additional benefits such as reduction of high blood pressure and weight loss. In the present study a feasible TLC method with reflectance/ fluorescence mode for simultaneous determination of GLM, EMPA and LING was established. Separation of the cited drugs was performed on aluminum plates pre-coated with silica gel 60 F254 and developed with (toluene: methanol: ethyl acetate (4: 3: 2 v/v/v)) as a mobile phase. The mentioned drugs were adequately detected after exposing the plate to concentrated (30 - 34%) hydrochloric acid vapor for 15 min. The was scanned in the reflectance/fluorescence mode at 228 nm excitation wavelength using 320 nm emission filter. The three drugs were well separated with Rf values of 0.73 ± 0.02, 0.59 ± 0.02 and 0.10 ± 0.02 for GLIM, EMPA and LING, respectively. The developed method was validated according to ICH guideline with linearity (2.61- 60, 5.53 –120 and 4.68 - 80 ng/band for GLIM, EMPA and LING, respectively) and precision (% RSD was ± 2.98 for GLIM, 2.76 for EMPA, 2.41 for LING). The correlation coefficients were 0.9915, 0.9940 and 0.9921 for GLIM, EMPA and LING, respectively. The developed method was successfully applied for the analysis of the cited drugs in their tablets and real human plasma samples with good accuracy and precision.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.